Odyral Pf (Dorzolamide)

Dorzolamide, the active ingredient in Odyral Pf, is a carbonic anhydrase inhibitor presented as an ophthalmic solution for ocular use. It is prescribed to lower intra‑ocular pressure in patients with primary open‑angle glaucoma and ocular hypertension. The formulation is designed for topical administration directly onto the eye surface, providing rapid onset of action.

GNH USA supplies Odyral Pf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Odyral Pf (dorzolamide) is used in the management of ocular conditions characterized by elevated intra‑ocular pressure. - Primary open-angle glaucoma: reduces intra‑ocular pressure to help prevent progressive optic nerve damage. - Ocular hypertension: lowers intra‑ocular pressure, decreasing the risk of developing glaucoma. - Secondary glaucoma: decreases aqueous humor production, aiding pressure control in secondary forms of glaucoma. - Glaucoma patients unsuitable for beta‑blocker therapy: offers a non‑beta‑blocker option for intra‑ocular pressure reduction.

Adverse ocular reactions have been reported with dorzolamide ophthalmic solution. Common Side Effects: - Eye irritation or burning sensation: mild discomfort that usually resolves quickly. - Bitter taste after administration: transient metallic taste perceived after the drop. - Blurred vision: temporary visual disturbance lasting minutes. - Transient headache: mild headache occurring shortly after use. Serious or Rare Side Effects: - Severe allergic reaction (e.g., angio‑edema, anaphylaxis): requires immediate medical attention. - Persistent eye pain or inflammation: may indicate a serious ocular event. - Vision loss: sudden decrease in visual acuity, seek urgent care.

Before using Odyral Pf, consider the following precautions to ensure safe and effective therapy. - Pregnancy: safety not established; use only if benefits outweigh risks. - Breastfeeding: unknown excretion; evaluate risk versus benefit. - Contact lens wearers: may cause discomfort; remove lenses before instillation and wait before reinserting. - Systemic carbonic anhydrase inhibitors: concurrent use may increase risk of systemic side effects. - Known hypersensitivity: discontinue if allergic reaction occurs. - Store at room temperature: keep in original container, protect from light and moisture.

Dorzolamide may interact with other medications; be aware of the following potential interactions. Major Interactions (Avoid): - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive inhibition may increase systemic side effects. - Sulfonamide antibiotics (e.g., sulfamethoxazole): cross‑reactivity risk for patients with sulfonamide allergy. Moderate Interactions (Monitor Closely): - Topical non‑steroidal anti‑inflammatory drugs: may increase ocular irritation. - Other intra‑ocular pressure‑lowering agents (e.g., beta‑blocker eye drops): monitor for excessive pressure reduction. - Oral potassium‑sparing diuretics: may potentiate systemic electrolyte disturbances.